Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines

Biochemical Pharmacology

Volumn 82, Issue 6, 2011, Pages 600-609

  Anshu, Ashish ^a   Thomas, Simmy ^a   Agarwal, Puneet ^a   Ibarra Rivera, Tannya R ^b   Pirrung, Michael C ^b   Schönthal, Axel H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bortezomib; Hematological tumors; Proteasome inhibitor; Syrbactin; Thapsigargin

Indexed keywords

ANTINEOPLASTIC AGENT; GLIDOBACTIN A; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN MCL 1; SURVIVIN; SYRBACTIN ANALOG; SYRINGOLIN A; SYRINGOLIN B; T 02; T 03; T 04; THAPSIGARGIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOBLOTTING; MOLECULAR STRUCTURE; OXIDATIVE STRESS; PEPTIDES, CYCLIC; PROTEASOME ENDOPEPTIDASE COMPLEX; UREA;

EID: 80051550182     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.06.031     Document Type: Article

References (40)

1. H.C. Drexler Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors PloS one 4 2009 e4161
2. S. Lonial, and L. Boise Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons Autophagy 2011 7
3. S.T. Nawrocki, J.S. Carew, K. Dunner Jr. , L.H. Boise, P.J. Chiao, and P. Huang Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells Cancer Res 65 2005 11510 11519 (Pubitemid 41821709)
4. D.J. McConkey, and K. Zhu Mechanisms of proteasome inhibitor action and resistance in cancer Drug Resist Updat 11 2008 164 179
5. J. Adams, and M. Kauffman Development of the proteasome inhibitor Velcade (Bortezomib) Cancer Invest 22 2004 304 311 (Pubitemid 38725184)
6. J. Sterz, I. von Metzler, J.C. Hahne, B. Lamottke, J. Rademacher, and U. Heider The potential of proteasome inhibitors in cancer therapy Expert Opin Investig Drugs 17 2008 879 895 (Pubitemid 351864325)
7. M.P. Curran, and K. McKeage Bortezomib: a review of its use in patients with multiple myeloma Drugs 69 2009 859 888
8. M.A. Dimopoulos, C. Chen, E. Kastritis, M. Gavriatopoulou, and S.P. Treon Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia Clinical Lymphoma, Myeloma & Leukemia 10 2010 110 117
9. I.M. Ghobrial, F. Hong, S. Padmanabhan, A. Badros, M. Rourke, and R. Leduc Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia J Clin Oncol 28 2010 1422 1428
10. J.P. Laubach, C.S. Mitsiades, A.M. Roccaro, I.M. Ghobrial, K.C. Anderson, and P.G. Richardson Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms macroglobulinemia Leukemia & Lymphoma 50 2009 694 702
11. L.R. Dick, and P.E. Fleming Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy Drug Discov Today 15 2010 243 249
12. J. Clerc, B.I. Florea, M. Kraus, M. Groll, R. Huber, and A.S. Bachmann Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines Chembiochem 10 2009 2638 2643
13. J. Clerc, M. Groll, D.J. Illich, A.S. Bachmann, R. Huber, and B. Schellenberg Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition Proc Natl Acad Sci USA 106 2009 6507 6512
14. M. Groll, B. Schellenberg, A.S. Bachmann, C.R. Archer, R. Huber, and T.K. Powell A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism Nature 452 2008 755 758 (Pubitemid 351521080)
15. C.R. Archer, D.L. Koomoa, E.M. Mitsunaga, J. Clerc, M. Shimizu, and M. Kaiser Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma Biochem Pharmacol 80 2010 170 178
16. C.S. Coleman, J.P. Rocete, D.J. Park, C.J. Wallick, B.J. Warn-Cramer, and K. Michel Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis Cell Prolif 39 2006 599 609 (Pubitemid 44760209)
17. M. Oka, Y. Nishiyama, S. Ohta, H. Kamei, M. Konishi, and T. Miyaki Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity J Antibiot 41 1988 1331 1337 (Pubitemid 18259415)
18. D. Ditzel Santos, A.W. Ho, O. Tournilhac, E. Hatjiharissi, X. Leleu, and L. Xu Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice Exp Hematol 35 2007 1366 1375 (Pubitemid 47302595)
19. T.C. Chen, W. Wang, E.B. Golden, S. Thomas, W. Sivakumar, and F.M. Hofman Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models Cancer Lett 2011 302
20. A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N.A. Petasis, and F. Hofman Multi-target inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2-inhibitory analog of celecoxib Blood 106 2005 4330 4338 (Pubitemid 41775944)
21. S. Thomas, S. Kotamraju, J. Zielonka, D.R. Harder, and B. Kalyanaraman Hydrogen peroxide induces nitric oxide and proteosome activity in endothelial cells: a bell-shaped signaling response J Free Radic Biol Med 42 2007 1049 1061 (Pubitemid 46356897)
22. X.M. Sun, M. Butterworth, M. MacFarlane, W. Dubiel, A. Ciechanover, and G.M. Cohen Caspase activation inhibits proteasome function during apoptosis Mol Cell 14 2004 81 93 (Pubitemid 38469911)
23. (2+)-ATPases Trends Pharmacol Sci 19 1998 131 135 (Pubitemid 28218535)
24. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
25. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 2006 621 681
26. H.G. Drexler, G. Gaedicke, and J. Minowada Isoenzyme studies in human leukemia-lymphoma cell lines - 1. Carboxylic esterase Leuk Res 9 1985 209 229 (Pubitemid 15120430)
27. J. Clerc, N. Li, D. Krahn, M. Groll, A.S. Bachmann, and B.I. Florea The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity Chem Commun 47 2011 385 387
28. C. Akgul Mcl-1 is a potential therapeutic target in multiple types of cancer Cell Mol Life Sci 66 2009 1326 1336
29. D.C. Altieri Survivin and IAP proteins in cell-death mechanisms Biochem J 430 2010 199 205
30. P. Gomez-Bougie, S. Wuilleme-Toumi, E. Menoret, V. Trichet, N. Robillard, and M. Philippe Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma Cancer Res 67 2007 5418 5424 (Pubitemid 46997282)
31. J. Michels, P.W. Johnson, and G. Packham Mcl-1 Int J Biochem Cell Biol 37 2005 267 271 (Pubitemid 39330187)
32. A. Nencioni, F. Hua, C.P. Dillon, R. Yokoo, C. Scheiermann, and M.H. Cardone Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis Blood 105 2005 3255 3262
33. S. Oyadomari, and M. Mori Roles of CHOP/GADD153 in endoplasmic reticulum stress Cell Death Differ 11 2004 381 389 (Pubitemid 38489416)
34. D.T. Rutkowski, S.M. Arnold, C.N. Miller, J. Wu, J. Li, and K.M. Gunnison Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins PLoS Biol 4 2006 e374
35. R.K. Reddy, C. Mao, P. Baumeister, R.C. Austin, R.J. Kaufman, and A.S. Lee Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation J Biol Chem 278 2003 20915 20924 (Pubitemid 36806399)
36. A.H. Schönthal Endoplasmic reticulum stress and autophagy as targets for cancer therapy Cancer Lett 275 2009 163 169
37. I. Tabas, and D. Ron Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress Nat Cell Biol 13 2011 184 190
38. S.J. Healy, A.M. Gorman, P. Mousavi-Shafaei, S. Gupta, and A. Samali Targeting the endoplasmic reticulum - stress response as an anticancer strategy Eur J Pharmacol 625 2009 234 246
39. S. Jagannath, M.A. Dimopoulos, and S. Lonial Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma Leuk Res 34 2010 1111 1118
40. K.R. Landis-Piwowar, V. Milacic, D. Chen, H. Yang, Y. Zhao, and T.H. Chan The proteasome as a potential target for novel anticancer drugs and chemosensitizers Drug Resist Updat 9 2006 263 273 (Pubitemid 46357634)